Early stage breast cancer: An approach to treatment (Review)

Oncology Reports

Volumn 4, Issue 6, 1997, Pages 1305-1310

  Theodossiou, Chris ^a,b   Schwarzenberger, Paul ^a   Espinoza Delgado, Igor ^a   Wynn, Raymond B ^a   Schapira, David V ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; Early stage disease

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; EARLY CANCER; HUMAN; LYMPH NODE METASTASIS; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT PLANNING;

EID: 0030929206     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics 1996. CA Cancer J Clin 47: 5-27, 1996.
2. Nemoto T, Vana J, Bedwari RN, et al: Management and survival of female breast cancer: results of a survey by the American College of Surgeons. Cancer 45: 2917-2924, 1980.
3. Fisher B, Slack NH, Bross DJ, et al: Cancer of the breast: size of neoplasm and prognosis. Cancer 24: 1071-1080, 1969.
4. Rosen PP, Groshen S, Saigo PE, Kinne DW and Hellman S: A long term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 7: 355-366, 1989.
5. Fisher B, Redmond C, Fisher ER, et al: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from the National Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6: 1076-1087, 1988.
6. Sigurdsson H, Baldetorp B, Borg A, et al: Indicators of prognosis in node negative breast cancer. N Engl J Med 320: 627-633, 1989.
7. McGuire WL: Estrogen receptor versus nuclear grade as prognostic factors in axillary node negative breast cancer. J Clin Oncol 6: 1071-1072, 1988.
8. Tandon AK, Clark GM, Chamness GC, et al: HER 2/new oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120-1128, 1989.
9. Tandon AK, Clark GM, Chamness GC, et al: Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297-302, 1990.
10. Nickolson S, Richard J, Sainsbury C, et al: Epidermal growth factor (EGF): results of a 6-year follow-up study in operable breast cancer with emphasis in the node negative subgroup. Br J Cancer 63: 146-150, 1991.
11. Wintzer HO, Zipfel I and Schulte-Monting J: Ki-67 immunostaining in node negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer 68: 549-557, 1991.
12. Daidone MG, Silvestrini R, D'Erico A, et al: Laminin receptors, collagenase IV and prognosis in node negative breast cancers. Int J Cancer 48: 529-532, 1991.
13. Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumor supressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 84: 845-855, 1992.
14. Ciatto S, Turco MRD, Bonardi R, et al: Non-palpable lesions of the breast detected by mammography: review of 1182 consecutive histologically confirmed cases. Eur J Cancer 30A: 40-44, 1994.
15. Fisher B, Anderson S, Redmond KC, et al: Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333: 1456-1461, 1995.
16. Chu A, Cope O, Russo R, et al: Patterns of loco-regional recurrence and results in stages I and II breast cancer treated by irradiation following limited surgery. Am J Clin Oncol (CCT) 7: 221-229, 1984.
17. Taylor ME, Perez CA, Halverson KT, et al: Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat Oncol Biol Phys 31: 753-764, 1995.
18. Pittinger TP, Maronian NC, Poulter CA, et al: Importance of margin status in outcome of breast-conserving surgery for carcinoma. Surgery 116: 605-609, 1994.
19. Silverstein M, Gierson E, Waisman J, et al: Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability. J Am Coll Surg 180: 700-704, 1995.
20. Petrek JA and Blackwood MM: Axillary dissection: currrent practice and technique. Curr Prob Surg 32: 309-313, 1995.
21. Seidman JD, Schnaper LA and Aisner SC: Relationship of the size of the invasive component of the primary breast carcinoma to axillary lymph node metastasis. Cancer 75: 65-71, 1995.
22. Reynolds JV, Mercer P, McDermott EW, et al: Audit of complete axillary dissection in early breast cancer. Eur J Cancer 30A: 148-149, 1994.
23. Giulano AE, Kirgan DM, Guenther JM, et al: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220: 391-401, 1994.
24. Uren RF, Howman-Giles RB, Thompson JF, Malouf D, Ramsey-Stewart G, Niesche FW and Renwick SB: Mammary lymphoscintigraphy in breast cancer. J Nucl Med 36: 1775-1780, 1995.
25. Giuliano AE, Kirgan DM, Guenther JM and Morton DL: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220: 391-401, 1994.
26. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW and Kranse D: Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 222: 394-401, 1995.
27. Recht A, Come SE, Gelman R, Goldstein M, et al: Integration of conservative surgery, radiotherapy and chemotherapy for the treatment of early stage, node positive breast cancer: sequencing, timing and outcome. J Clin Oncol 9: 1662-1667, 1991.
28. Recht A, Come SE, Henderson C, et al: The sequencing of chemotherapy and radiation therapy after conservative surgery for early stage breast cancer. N Engl J Med 334: 1356-1441, 1996.
29. Bonadonna G, Valagussa BS, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. N Engl J Med 332: 901-906, 1995.
30. Fisher B, Brown AN, Dimitrov N, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8: 1483-1496, 1990.
31. Coombes RC, Bliss JM, Wils F, et al: Adjuvant cyclophosphamide, methotrexate and fluorouracil versus fluorouracil, epirubicin and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. J Clin Oncol 14: 35-45, 1996.
32. Wood WC, Budman DR, Kozrum AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node positive breast carcinoma. N Engl J Med 330: 1253-1259, 1994.
33. Jaiyesimi I, Buzdar A, Decker D, et al: Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13: 513-529, 1995.
34. Breast Cancer Trials Committee, Scottish Cancer Trials Office: Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet ii: 171-175, 1987.
35. Ribeiro G and Swindell R: The Christie Hospital adjuvant tamoxifen trial - status at 10 years. Br J Cancer 57: 601-603, 1988.
36. Fisher B, Redmond C, Legault-Poisson S, et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8: 1005-1018, 1990.
37. Rivkin S, Green S, O'Sullivan J, et al: Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 14: 45-51, 1995.
38. Hayes DF, Van Zyl JA, Hacking A, et al: Randomized comparison of tamoxifen and two separate doses of toromifene in postmenopausal patients with metastatic cancer. J Clin Oncol 13: 2556-2566, 1995.
39. Peters WP, Ross M, Vredenburgh JJ, et al: High dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high risk primary breast cancer. J Clin Oncol 11: 1132-1143, 1993.
40. Harris CC and Hollstein M: Clinical implications of the p53 tumor suppressor gene. N Engl J Med 319: 1318-1327, 1993.
41. Finn OJ, Jerome KR, Henderson RA, Pecher G, et al: MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 145: 61-89, 1995.
42. Soussi T: The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. Immunol Today 17: 354-356, 1996.
43. Jerome KR, Barnd DL, Bendt KM, Boyer CM, et al: Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 51: 2908-2916, 1991.
44. Ezzell C: Cancer 'vaccines': an idea whose time has come? J NIH Res 7: 46-49, 1995.